The Paris-Saclay Cancer Cluster (PSCC) is a European-scale oncology biocluster with global ambitions, created to accelerate the translation of cutting-edge cancer science into precision therapies, diagnostics and technologies.

As the first biocluster established under the French Government’s France 2030 investment plan, PSCC brings together more than 180 start-ups, biotech companies, pharmaceutical groups, investors, research organisations, hospitals and public institutions. Its role is to connect promising oncology innovators with the expertise, infrastructure, capital and industrial partners needed to de-risk development and accelerate growth.

PSCC offers start-ups access to a curated ecosystem of scientific and clinical expertise, mentoring, data resources, laboratory infrastructure, funding opportunities and strategic connections. Anchored at Campus Grand Parc, in greater Paris, PSCC provides a dedicated hub where entrepreneurs, researchers, clinicians, investors and industry partners can collaborate daily to transform scientific breakthroughs into clinical and industrial impact.